<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1005" relname="span">Tyrosine kinase inhibitors</segment>
<segment id="3" parent="2" relname="restatement">( TKIs )</segment>
<segment id="4" parent="1004" relname="same_unit">are widely used drugs as a targeted strategy for cancer treatment with the aim</segment>
<segment id="5" parent="1004" relname="elaboration">of prolonging progression-free survival .</segment>
<segment id="6" parent="1007" relname="span">Deregulated tyrosine kinase activity of the BCR-ABL oncoprotein is the biochemical hallmark of Philadelphia chromosome-positive</segment>
<segment id="7" parent="6" relname="restatement">( Ph+ )</segment>
<segment id="8" parent="1006" relname="same_unit">hematological malignancies .</segment>
<segment id="9" parent="1001" relname="joint">Currently , several generations of BCR-ABL TKIs are in clinical use for treatment of these malignancies .</segment>
<segment id="10" parent="1001" relname="joint">Introduction of the second-generation TKIs , nilotinib and dasatinib as first-line treatment resulted in rapid and deep reduction of BCR/ABL1 allele transcripts ,</segment>
<segment id="11" parent="1001" relname="joint">and this provided a possibility for long-term survival in CML .</segment>
<segment id="12" parent="1012" relname="span">In addition to CML , several other patient populations were identified</segment>
<segment id="13" parent="12" relname="elaboration">that undoubtedly benefited from TKI treatment .</segment>
<segment id="14" parent="1015" relname="span">Patients with Ph+ adult acute lymphoblastic leukemia</segment>
<segment id="15" parent="14" relname="elaboration">( ALL )</segment>
<segment id="16" parent="1014" relname="same_unit">may also benefit from an alternate TKI therapy .</segment>
<segment id="17" parent="1017" relname="span">In the treatment of pediatric patients with Ph+ ALL</segment>
<segment id="18" parent="17" relname="elaboration">the addition of TKIs to conventional chemotherapy has improved outcomes of patients .</segment>
<segment id="19" parent="1020" relname="attribution">It has long been known</segment>
<segment id="20" parent="1020" relname="span">that second-generation TKIs may have side effects</segment>
<segment id="21" parent="1021" relname="span">as nilotinib can potentiate a prothrombotic state</segment>
<segment id="22" parent="23" relname="concession">while dasatinib is known to cause platelet dysfunction</segment>
<segment id="23" parent="1022" relname="span">e.g. impaired collagen-induced platelet adhesion and aggregation .</segment>
<segment id="24" parent="1024" relname="span">Although both drugs bind to the ATP binding site of the kinase domain of the BCR/ABL protein</segment>
<segment id="25" parent="24" relname="elaboration">they have different off target inhibitory effect on several other tyrosine kinases .</segment>
<segment id="26" parent="1026" relname="span">Dasatinib is a potent multikinase inhibitor ,</segment>
<segment id="27" parent="26" relname="elaboration">including c-KIT , EPHA2 , platelet-derived growth factor receptor-Î² , and SFKs .</segment>
<segment id="28" parent="1029" relname="span">Nilotinib is also a second generation TKI with a broad inhibitory spectrum of various tyrosine kinases</segment>
<segment id="29" parent="28" relname="elaboration">( PDGFR , c-KIT , ARG , EPHB4 ) ,</segment>
<segment id="30" parent="1028" relname="span">but it does not inhibit SFKs .</segment>
<segment id="31" parent="1016" relname="joint">Previous in vitro and ex vivo studies with dasatinib have demonstrated a faulty platelet aggregation .</segment>
<segment id="32" parent="1016" relname="joint">On the contrary nilotinib has no effect on platelet aggregation , at all .</segment>
<segment id="33" parent="1016" relname="joint">Therefore , we used nilotinib as a negative control in our experiments .</segment>
<segment id="34" parent="1035" relname="span">Sarcoma family kinases</segment>
<segment id="35" parent="34" relname="elaboration">( SFKs )</segment>
<segment id="36" parent="1034" relname="same_unit">are critical regulators of platelet signaling and activation .</segment>
<segment id="37" parent="1037" relname="span">These kinases play a central role</segment>
<segment id="38" parent="37" relname="elaboration">in mediating rapid response of platelets to vascular injury .</segment>
<segment id="39" parent="1016" relname="joint">They transmit activation signals from several various platelet receptors .</segment>
<segment id="40" parent="1041" relname="span">There are numerous members of this group</segment>
<segment id="41" parent="1042" relname="joint">and among the SFKs Lyn , Fyn , and Src have been implicated in activation of the GPVI receptor and the integrin receptor signaling</segment>
<segment id="42" parent="1043" relname="span">and are frequently studied proteins</segment>
<segment id="43" parent="42" relname="circumstance">as they are present in both human and mouse platelets .</segment>
<segment id="44" parent="1041" relname="elaboration">TKIs have a different off-target multikinase inhibitory effect .</segment>
<segment id="45" parent="1045" relname="span">Comprehensive drug-protein interaction profiles were described</segment>
<segment id="46" parent="45" relname="purpose">to predict the potential side effects of BCR-ABL TKIs .</segment>
<segment id="47" parent="1049" relname="attribution">It was found</segment>
<segment id="48" parent="1050" relname="span">that the most prominent dasatinib-targeted SFKs are Lyn , Fyn , and Src , kinases and their negative regulator C-terminal Src kinase</segment>
<segment id="49" parent="48" relname="elaboration">( Csk ) ,</segment>
<segment id="50" parent="1049" relname="same_unit">but nilotinib does not bind to these kinases .</segment>
<segment id="51" parent="1053" relname="span">During vascular injury it is primarily the subendothelial collagen</segment>
<segment id="52" parent="51" relname="elaboration">that activates platelets</segment>
<segment id="53" parent="1052" relname="joint">and result in subsequent platelet aggregation .</segment>
<segment id="54" parent="1054" relname="span">A population of the collagen-adhered platelets responds</segment>
<segment id="55" parent="1055" relname="span">by surface exposure of the procoagulant phosphatidylserine</segment>
<segment id="56" parent="55" relname="restatement">( PS ) .</segment>
<segment id="57" parent="1057" relname="span">This surface expressed PS facilitates the binding of coagulation factors</segment>
<segment id="58" parent="57" relname="elaboration">and by this promotes thrombin generation .</segment>
<segment id="59" parent="1016" relname="joint">In addition , platelets participate in fibrin formation</segment>
<segment id="60" parent="1016" relname="joint">and regulate the process of clot retraction .</segment>
<segment id="61" parent="62" relname="attribution">We intended to investigate</segment>
<segment id="62" parent="1061" relname="span">whether dasatinib also affects the platelet procoagulant activity and thereby coagulation .</segment>
<segment id="63" parent="1063" relname="span">For this reason , we examined the in vitro and ex vivo effects of dasatinib on platelet procoagulant response in dasatinib treated platelets of healthy volunteers and in samples</segment>
<segment id="64" parent="63" relname="elaboration">derived from CML patients on dasatinib therapy .</segment>
<segment id="65" parent="66" relname="attribution">We found</segment>
<segment id="66" parent="1064" relname="span">that at therapeutic concentration dasatainib , but not nilotinib , has a strong inhibitory effect on platelet procoagulant activity and on clot retraction both in non activated as well as in convulxin activated platelets .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="joint"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="multinuc" parent="1003" relname="span"/>
<group id="1005" type="span" parent="1004" relname="same_unit"/>
<group id="1006" type="multinuc" parent="1003" relname="elaboration"/>
<group id="1007" type="span" parent="1006" relname="same_unit"/>
<group id="1011" type="span" parent="1001" relname="joint"/>
<group id="1012" type="span" parent="1013" relname="preparation"/>
<group id="1013" type="span" parent="1011" relname="span"/>
<group id="1014" type="multinuc" parent="1016" relname="preparation"/>
<group id="1015" type="span" parent="1014" relname="same_unit"/>
<group id="1016" type="multinuc" parent="1013" relname="span"/>
<group id="1017" type="span" parent="1016" relname="joint"/>
<group id="1019" type="span" parent="1016" relname="joint"/>
<group id="1020" type="span" parent="1019" relname="span"/>
<group id="1021" type="span" parent="20" relname="circumstance"/>
<group id="1022" type="span" parent="21" relname="elaboration"/>
<group id="1024" type="span" parent="1016" relname="joint"/>
<group id="1026" type="span" parent="1016" relname="joint"/>
<group id="1028" type="span" parent="1016" relname="joint"/>
<group id="1029" type="span" parent="30" relname="concession"/>
<group id="1034" type="multinuc" parent="1016" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="same_unit"/>
<group id="1037" type="span" parent="1016" relname="joint"/>
<group id="1040" type="span" parent="1016" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="span"/>
<group id="1042" type="multinuc" parent="40" relname="elaboration"/>
<group id="1043" type="span" parent="1042" relname="joint"/>
<group id="1045" type="span" parent="1016" relname="joint"/>
<group id="1047" type="span" parent="1016" relname="joint"/>
<group id="1048" type="span" parent="1047" relname="span"/>
<group id="1049" type="multinuc" parent="1048" relname="span"/>
<group id="1050" type="span" parent="1049" relname="same_unit"/>
<group id="1051" type="span" parent="1048" relname="elaboration"/>
<group id="1052" type="multinuc" parent="1051" relname="span"/>
<group id="1053" type="span" parent="1052" relname="joint"/>
<group id="1054" type="span" parent="1052" relname="elaboration"/>
<group id="1055" type="span" parent="54" relname="means"/>
<group id="1057" type="span" parent="1016" relname="joint"/>
<group id="1061" type="span" parent="1016" relname="joint"/>
<group id="1063" type="span" parent="1016" relname="joint"/>
<group id="1064" type="span" parent="1016" relname="joint"/>
	</body>
</rst>
